SCHEMBL7183339

SCHEMBL7183339

Cc1cc(C(C)(C)C)cc(C)c1C(=O)[PH](=O)Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
RAB9A P51151 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
NPC1 O15118 1/20 0.38
RXRB P28702 5/20 0.37
RXRA P19793 4/20 0.37
RXRG P48443 3/20 0.37
ALDH1A1 P00352 2/20 0.37
EGFR P00533 1/20 0.36
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ESRRG P62508 1/20 0.35
EPHX1 P07099 3/20 0.35
MEN1 O00255 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
NR1H4 Q96RI1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189164 0.86 LMNA (0.41) LMNARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL7183783 0.86 RXRA (0.43) LMNARAB9AMRGPRX4NPC1RXRB
SCHEMBL7179814 0.83 RXRA (0.41) LMNARAB9ANPC1RXRBRXRA
SCHEMBL7175024 0.83 GPR52 (0.45) LMNARAB9ANPC1KDM4EHPGD
SCHEMBL7180860 0.82 RXRA (0.40) RAB9ANPC1RXRBRXRARXRG
SCHEMBL7184990 0.81 MAPT (0.40) RAB9ANPC1RXRBRXRARXRG
SCHEMBL7189036 0.81 MAPT (0.40) RAB9ANPC1RXRBRXRARXRG
SCHEMBL7188533 0.81 MAPT (0.40) RAB9ANPC1RXRBRXRARXRG
SCHEMBL7181971 0.81 MAPT (0.40) RAB9ANPC1RXRBRXRARXRG
SCHEMBL7177692 0.81 LMNA (0.39) LMNARAB9ANPC1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885RAB9A 1818/4885MRGPRX4 3913/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885RAB9A 2155/4885MRGPRX4 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.